January 17, 2024 07:03 AM EST
People
China
Pharma

As­traZeneca reshuf­fles Chi­na lead­er­ship, sets up bio­phar­ma group to mir­ror glob­al struc­ture

Amber Tong

As­traZeneca’s Chi­na group has reshuf­fled its lead­er­ship and set up a new bio­phar­ma group fol­low­ing the de­par­ture of its gen­er­al man­ag­er in on­col­o­gy, ac­cord­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

A service from the Financial Times